Maximum Safe Doses — MCQs
Regarding malignant hyperthermia, which statement about local anesthetics is correct?
A patient presented with rigidity, tremors, and trismus after being administered an anesthetic agent. Which anesthetic agent is most likely to have been administered?
What is the maximum concentration allowed for epidural block?
Which local anesthetic has the highest protein binding capacity?
A young male was administered regional anesthesia with 0.25% bupivacaine. The patient became unresponsive, and the pulse became unrecordable. What is the best management in this situation?
What is the maximum dose of plain lignocaine (in mg) for adults?
Which is correct about the anesthetic drugs X and Y in the image shown? (Recent NEET Pattern 2016-17)
True regarding EMLA is
Which of the following anesthetic agents does not trigger malignant hyperthermia?
The maximum dosage of a local anesthetic agent like lidocaine must be reduced when it is used in combination with a CNS and/or respiratory depressant because, it may result in?
Maximum Safe Doses Indian Medical PG Practice Questions and MCQs
Question 1: Regarding malignant hyperthermia, which statement about local anesthetics is correct?
- A. Local anesthetics are safe to use in malignant hyperthermia-susceptible patients (Correct Answer)
- B. Amide local anesthetics can trigger malignant hyperthermia
- C. Ester local anesthetics are contraindicated in malignant hyperthermia
- D. Local anesthetics should be avoided in patients with family history of malignant hyperthermia
Explanation: ***Local anesthetics are safe to use in malignant hyperthermia-susceptible patients*** - Malignant hyperthermia (**MH**) is primarily triggered by **volatile anesthetic agents** and **succinylcholine**. - Local anesthetics, whether **amide** or **ester** types, do not trigger MH and are considered safe for use in **MH-susceptible individuals**. *Amide local anesthetics can trigger malignant hyperthermia* - This statement is incorrect. **Amide local anesthetics** (e.g., lidocaine, bupivacaine) have **not been implicated** as triggers for malignant hyperthermia. - The mechanism of action of amide local anesthetics differs significantly from that of known MH triggers, which affect **calcium regulation** in muscle cells. *Ester local anesthetics are contraindicated in malignant hyperthermia* - This statement is incorrect. **Ester local anesthetics** (e.g., procaine, tetracaine) are also **safe** to use in patients susceptible to malignant hyperthermia. - Their metabolism and mechanism similarly do not interact with the **ryanodine receptor** or the pathways leading to uncontrolled calcium release characteristic of MH. *Local anesthetics should be avoided in patients with family history of malignant hyperthermia* - This statement is incorrect. A **family history of malignant hyperthermia (MH)** indicates the patient might be MH-susceptible, but local anesthetics are still **safe to use** in these individuals. - Avoiding local anesthetics in such patients would be an **unnecessary restriction** and deny them effective pain management options.
Question 2: A patient presented with rigidity, tremors, and trismus after being administered an anesthetic agent. Which anesthetic agent is most likely to have been administered?
- A. Halothane (Correct Answer)
- B. Nitrous Oxide (N2O)
- C. Thiopentone sodium
- D. Etomidate
Explanation: ***Halothane*** - The combination of **rigidity**, **tremors**, and **trismus** after an anesthetic agent suggests **malignant hyperthermia (MH)**, a rare but life-threatening inherited condition. - **Halothane (and other volatile anesthetics)**, along with succinylcholine, are known triggers for malignant hyperthermia. *Nitrous Oxide (N2O)* - While an anesthetic agent, **nitrous oxide** is not a known trigger for **malignant hyperthermia**. - It works by modulating **NMDA receptors** and does not typically cause rigidity, tremors, or trismus as a side effect. *Thiopentone sodium* - **Thiopentone sodium** is a **barbiturate** anesthetic and is not associated with triggering **malignant hyperthermia**. - Its effects primarily involve potentiation of **GABA-A receptors**, leading to sedation and hypnosis. *Etomidate* - **Etomidate** is a short-acting intravenous anesthetic that is not a known trigger for **malignant hyperthermia**. - It is typically associated with minimal cardiovascular depression but can cause **adrenocortical suppression** with prolonged use.
Question 3: What is the maximum concentration allowed for epidural block?
- A. Chlorprocaine (Correct Answer)
- B. Lidocaine
- C. Ropivacaine
- D. Bupivacaine
Explanation: ***Chlorprocaine*** - **Chlorprocaine** is an ester-type local anesthetic that can be safely used in higher concentrations for epidural blocks up to **3%**, due to its rapid hydrolysis by plasma pseudocholinesterase, leading to a very short half-life and reduced systemic toxicity. - Its rapid metabolism minimizes the risk of accumulation and systemic toxicity, making it a suitable choice when a dense block is needed and a short duration of action is acceptable. *Lidocaine* - **Lidocaine** is an amide-type local anesthetic commonly used in epidural blocks, but its maximum concentration for this application is typically limited to **2%** to avoid systemic toxicity. - Higher concentrations of lidocaine are associated with an increased risk of neurological and cardiovascular adverse effects. *Ropivacaine* - **Ropivacaine** is an amide-type local anesthetic that is less cardiotoxic than bupivacaine, with common concentrations for epidural use ranging from **0.2% to 1%**. - Its maximum concentration is significantly lower than chlorprocaine due to its longer duration of action and potential for systemic toxicity at higher doses. *Bupivacaine* - **Bupivacaine** is a potent amide-type local anesthetic with a high risk of cardiotoxicity, and its maximum concentration for epidural use is generally restricted to **0.5%** or even less for continuous infusions. - Using concentrations above this limit significantly increases the risk of severe cardiovascular complications, including arrhythmias and cardiac arrest.
Question 4: Which local anesthetic has the highest protein binding capacity?
- A. Tetracaine (Correct Answer)
- B. Procaine
- C. Lidocaine
- D. Prilocaine
Explanation: ***Tetracaine*** - **Tetracaine** has a very high protein binding capacity (around 80%), which correlates with its **long duration of action** and high potency. - High protein binding means less free drug is available to reach nerve membranes immediately, but it also provides a reservoir for sustained release, contributing to its prolonged anesthetic effect. *Lidocaine* - **Lidocaine** has an intermediate protein binding capacity (around 60-70%), making it a **medium-duration** local anesthetic. - Its protein binding is lower than tetracaine, hence it has a shorter clinical duration of action compared to tetracaine. *Prilocaine* - **Prilocaine** has a relatively low protein binding capacity (around 55%), leading to a **shorter duration of action** compared to lidocaine and tetracaine. - Its lower protein binding also contributes to its relatively lower potency. *Procaine* - **Procaine** has the lowest protein binding capacity among the listed options (around 5-10%), making it a **short-acting** local anesthetic. - Its rapid metabolism by plasma pseudocholinesterases further contributes to its limited duration of action.
Question 5: A young male was administered regional anesthesia with 0.25% bupivacaine. The patient became unresponsive, and the pulse became unrecordable. What is the best management in this situation?
- A. ECPR with calcium
- B. ECPR with dobutamine
- C. ECPR with 20% intralipid (Correct Answer)
- D. ECPR with sodium bicarbonate
Explanation: ***ECPR with 20% intralipid*** - The scenario describes **Local Anesthetic Systemic Toxicity (LAST)**, likely due to bupivacaine, leading to cardiovascular collapse. - **Intralipid 20%** is the first-line treatment for LAST-induced cardiovascular toxicity, as it acts as a lipid sink for the lipophilic local anesthetic. *ECPR with calcium* - While calcium may be used in certain cardiac arrest scenarios, it is **not the primary treatment for bupivacaine-induced cardiovascular collapse** and LAST. - Calcium might offer some cardiac support but does not directly neutralize the local anesthetic's toxic effects. *ECPR with dobutamine* - **Dobutamine is an inotropic agent** used to improve cardiac contractility but is not indicated as a primary rescue therapy for severe LAST. - It would not address the underlying toxicity caused by bupivacaine and could potentially worsen the situation by increasing myocardial oxygen demand without reversing toxin effects. *ECPR with sodium bicarbonate* - **Sodium bicarbonate** is used to treat metabolic acidosis and can be beneficial in certain drug overdoses to enhance excretion or stabilize cardiac membranes. - However, it is **not the primary or most effective treatment for bupivacaine-induced LAST** and cardiovascular collapse compared to lipid emulsion therapy.
Question 6: What is the maximum dose of plain lignocaine (in mg) for adults?
- A. 300 (Correct Answer)
- B. 500
- C. 700
- D. 1000
Explanation: ***300 mg*** - The maximum recommended dose of **plain lidocaine** (without epinephrine) for adults is typically **300 mg** or 4.5 mg/kg, whichever is less. - Exceeding this dose can increase the risk of **systemic toxicity**, including central nervous system and cardiovascular effects. *500 mg* - This dose is generally considered the maximum for **lidocaine with epinephrine** in adults, as **epinephrine** causes vasoconstriction and delays systemic absorption of lidocaine. - For **plain lidocaine**, 500 mg would be an overdose and significantly increase the risk of toxicity. *700 mg* - This is well above the recommended maximum dose for both plain lidocaine and lidocaine with epinephrine, posing a **severe risk of toxicity**. - Such a high dose could lead to **seizures**, cardiac arrhythmias, and even **cardiac arrest**. *1000 mg* - This dose is extremely dangerous and far exceeds any recommended maximum for lidocaine, regardless of whether it contains epinephrine. - Administration of 1000 mg of lidocaine would almost certainly result in **severe and potentially fatal toxicity**.
Question 7: Which is correct about the anesthetic drugs X and Y in the image shown? (Recent NEET Pattern 2016-17)
- A. Drug X and Y have equally fast onset of action
- B. Drug X and Y have equally fast onset of action but potency of X is more than Y
- C. Drug Y is more fast acting than X
- D. Drug X is more fast acting than Y (Correct Answer)
Explanation: ***Drug X is more fast acting than Y*** - The **oil:gas partition coefficient** for Drug X is lower than for Drug Y. A lower oil:gas partition coefficient typically correlates with a **faster onset of action** for inhaled anesthetics as it indicates lower solubility in blood and tissues, allowing for quicker equilibration in the brain. - While MAC is plotted against oil:gas partition coefficient, the question specifically asks about **onset of action**, which is primarily influenced by blood-gas solubility rather than oil-gas solubility. However, an anesthetic with lower oil-gas solubility (like X) would generally also have lower blood-gas solubility, leading to faster onset. *Drug Y is more fast acting than X* - Drug Y has a **higher oil:gas partition coefficient** compared to Drug X, indicating greater lipid solubility. - A higher oil:gas partition coefficient generally correlates with a **slower onset of action** for inhaled anesthetics, as more drug dissolves in lipids before reaching the brain. *Drug X and Y have equally fast onset of action* - The graph clearly shows that Drug X and Drug Y have different **oil:gas partition coefficients**. - Since the partition coefficients are different, their **solubility characteristics** and therefore their clinical onset of action would also be different. *Drug X and Y have equally fast onset of action but potency of X is more than Y* - Onset of action is **not equal** for X and Y due to their differing oil:gas partition coefficients. - Potency, represented by **MAC** (Minimum Alveolar Concentration), is inversely related to the oil:gas partition coefficient for many inhaled anesthetics. From the graph, Drug X has a higher MAC value than Drug Y (meaning it is **less potent** but acts faster).
Question 8: True regarding EMLA is
- A. used for bilateral nerve block
- B. used as general anaesthesia in pediatric use
- C. Its mixture of 25 mg/g Lidocaine + 25 mg/g prilocaine used for skin anaesthesia (Correct Answer)
- D. None of the above
Explanation: ***Its mixture of 25 mg/g Lidocaine + 25 mg/g prilocaine used for skin anaesthesia*** - **EMLA** (Eutectic Mixture of Local Anesthetics) is a cream containing a 1:1 ratio of **lidocaine** and **prilocaine**. - It is primarily used for **topical anesthesia** of the skin, offering pain relief during superficial procedures like venipuncture or skin biopsies. *used for bilateral nerve block* - **EMLA cream** is a topical anesthetic and is not suitable for **nerve blocks** due to its formulation and limited depth of penetration. - Nerve blocks require injection of local anesthetics directly near nerves. *used as general anaesthesia in pediatric use* - **EMLA cream** provides **local analgesia** and is not formulated or intended for use as a **general anesthetic**. - General anesthesia requires systemic administration of drugs to induce a state of unconsciousness. *None of the above* - This option is incorrect because the third statement accurately describes the composition and primary use of **EMLA cream**.
Question 9: Which of the following anesthetic agents does not trigger malignant hyperthermia?
- A. Isoflurane
- B. Suxamethonium
- C. Halothane
- D. Thiopentone (Correct Answer)
Explanation: ***Thiopentone*** - **Thiopentone** is an **intravenous anesthetic agent** that does not trigger **malignant hyperthermia** because it does not interact with the **ryanodine receptor (RyR1)** or lead to uncontrolled calcium release from the sarcoplasmic reticulum. - It is a **barbiturate** and its mechanism of action involves enhancing the effect of **GABA** at the GABA-A receptor, unrelated to the calcium dysregulation seen in malignant hyperthermia. *Isoflurane* - **Isoflurane** is a **volatile anesthetic agent** (inhaled) known to be a potent trigger of **malignant hyperthermia** in susceptible individuals. - It directly activates the **ryanodine receptor type 1 (RyR1)**, leading to a massive and uncontrolled release of calcium from the **sarcoplasmic reticulum** in skeletal muscle cells. *Suxamethonium* - **Suxamethonium** (succinylcholine) is a **depolarizing neuromuscular blocker** that can trigger or exacerbate **malignant hyperthermia**, especially when given with volatile anesthetics. - It causes muscle fasciculations and can lead to a sustained muscle contraction and metabolic derangements characteristic of the condition. *Halothane* - **Halothane** is a prototype **volatile anesthetic agent** and is one of the most well-known and potent triggers of **malignant hyperthermia**. - Its use has significantly decreased due to its association with malignant hyperthermia and hepatotoxicity, but it serves as a classic example of an agent that causes massive calcium release from the **sarcoplasmic reticulum**.
Question 10: The maximum dosage of a local anesthetic agent like lidocaine must be reduced when it is used in combination with a CNS and/or respiratory depressant because, it may result in?
- A. Seizures
- B. Coma
- C. Death
- D. All of the above (Correct Answer)
Explanation: ### Explanation **1. The Underlying Medical Concept** Local anesthetics (LAs) like lidocaine are CNS depressants when they reach toxic systemic levels. While they initially cause excitatory symptoms (due to inhibition of inhibitory pathways), higher concentrations lead to generalized CNS depression. When lidocaine is administered alongside other **CNS or respiratory depressants** (such as opioids, benzodiazepines, or barbiturates), an **additive or synergistic effect** occurs. Furthermore, respiratory depressants increase arterial $PCO_2$ (hypercapnia) and decrease pH (acidosis). Acidosis decreases the seizure threshold and increases the fraction of ionized drug, while hypercapnia increases cerebral blood flow, delivering more lidocaine to the brain. This potentiation significantly lowers the threshold for **Systemic Toxicity (LAST)**. **2. Analysis of Options** * **A. Seizures:** This is the classic sign of moderate-to-severe CNS toxicity. The combined effect of drugs lowers the seizure threshold, making neurotoxicity more likely even at "standard" doses. * **B. Coma:** As drug levels rise or are potentiated by other depressants, the initial excitatory phase (seizures) is rapidly followed by profound CNS depression, leading to a comatose state. * **C. Death:** Severe toxicity results in respiratory arrest (due to medullary depression) and cardiovascular collapse (negative inotropy and arrhythmias). Without immediate resuscitation, this progression leads to fatality. * **D. All of the above:** Since the toxic progression follows a continuum from excitation to depression to death, all outcomes are possible when lidocaine is combined with other depressants. **3. High-Yield Clinical Pearls for NEET-PG** * **Maximum Dose of Lidocaine:** 3 mg/kg (plain) and 7 mg/kg (with adrenaline). * **Early Signs of Toxicity:** Perioral numbness, metallic taste, and tinnitus. * **Treatment of Choice for LAST:** **Intravenous Lipid Emulsion (20% Intralipid)**. * **Hypercapnia & Toxicity:** Always remember that an increase in $PaCO_2$ is the most potent factor in increasing the CNS toxicity of local anesthetics.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free